 Phase II trial interferon gamma monoclonal antibody pancreatic cancer biologic clinical effects Thirty patients advanced measurable pancreatic adenocarcinoma phase II trial recombinant interferon gamma Biogen Cambridge MA days monoclonal antibody Mab Centocor Malvern PA mg autologous leukocytes days interferon infusion effect single interferon gamma treatment natural antibody-dependent cellular cytotoxicity ADCC Fc receptor occupancy antibody human leukocyte antigen-DR HLA-DR expression monocytes lymphocytes Toxicity modest II fever nausea vomiting hepatotoxicity patients nonassessable response assessable patients objective response complete remission duration months Stable disease months patients median survival group months Analysis cytotoxicity data treatment reduced natural cytotoxic activity patients normal volunteers significant improvement natural cytotoxic activity normal levels hours interferon gamma infusion augmented antibody-dependent cellular cytotoxicity HLA-DR expression monocytes lymphocytes capacity lymphocytes monocytes Mab vitro assays ADCC presence antibody excess improved cytolytic activity spite favorable modulation cytolytic activity improved ability effector cells Mab adequate clinical efficacy treatment patients pancreatic adenocarcinoma dose schedule interferon gamma Mab Future trials alternate schedules Mab hope tumor antigen saturation circulating levels infused antibody